CagriSema

CagriSema (Inj)

CagriSema is a fixed-dose combination of cagrilinitide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), both dosed at 2.4 mg weekly. Developed by Novo Nordisk, it leverages complementary mechanisms — amylin receptor agonism and GLP-1 receptor agonism — to produce additive and potentially synergistic weight loss superior to either agent alone. Phase 3 REDEFINE trials are ongoing.

Dosing Protocols

Phase 2 trial doses: cagrilinitide 2.4 mg + semaglutide 2.4 mg weekly, escalated over 16–20 weeks. Phase 3 REDEFINE trials (ongoing 2024–2025) are expected to confirm efficacy. Target body weight reduction: 20–25%+ over 68 weeks. Both components are administered as a combined subcutaneous injection once weekly.

Benefits

• Superior weight loss vs. semaglutide alone (up to 25% body weight in Phase 2)
• Dual mechanism: amylin + GLP-1 receptor activation
• Significant improvement in glycemic control
• Reduces cardiovascular risk factors (blood pressure, lipids)
• Reduces waist circumference and visceral fat
• Once-weekly dosing of both components in a single injection
• Maintains lean mass better than some single-agent weight loss approaches
• Addresses multiple satiety pathways simultaneously

Mechanism of Action

CagriSema combines two complementary mechanisms. Semaglutide activates GLP-1 receptors in the hypothalamus, gut, and pancreas, reducing appetite, slowing gastric emptying, and stimulating insulin release. Cagrilinitide activates amylin receptors in the area postrema and hypothalamus, independently reducing food intake and slowing gastric emptying via a different receptor system. The combination targets multiple satiety pathways simultaneously, producing greater caloric restriction and weight loss than either agent alone.

Side Effects

• Nausea and vomiting (more frequent than semaglutide monotherapy)
• Diarrhea and constipation
• Decreased appetite
• Fatigue
• Injection site reactions
• Headache
• Elevated heart rate (class effect of GLP-1 RAs)

Side Effect Management

Standard GLP-1/amylin tolerability management applies: slow dose escalation, eating smaller meals, staying hydrated, and avoiding high-fat foods that worsen nausea. If GI side effects are severe, temporary dose reduction may be warranted. Medical supervision recommended for this combination therapy.

Contraindications

• Personal or family history of medullary thyroid carcinoma or MEN 2
• Pregnancy and lactation
• Pancreatitis history
• Severe GI disease
• Severe renal or hepatic impairment

Research Citations

• Frias JP et al. (2023). CagriSema in type 2 diabetes. New England Journal of Medicine. DOI: 10.1056/NEJMoa2307384
• Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes. Lancet Diabetes Endocrinology. DOI: 10.1016/S2213-8587(23)00327-7

---